Madrigal Pharmaceuticals Inc (MDGL): Next-Year EPS Estimate 259.35%
As of 2026-06-11, Madrigal Pharmaceuticals Inc (MDGL) has a next-year EPS growth estimate of 259.35%.
On 2026-06-11, analyst consensus for MDGL's next-year EPS growth shifted from 260.99% to 259.35% — a negative change of 1.64 percentage points. Current-year growth is projected at 48.79%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 259.35%
- EPS growth this year
- 48.79%
- EPS next quarter (est)
- -$2.49
- Last price
- $474.28
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 259.35% | 48.79% | -$2.49 | $474.28 |
| 2026-06-10 | 260.99% | 49.05% | -$2.38 | $471.32 |
| 2026-06-09 | 260.99% | 49.05% | -$2.38 | $476.89 |
| 2026-06-08 | 260.99% | 49.05% | -$2.38 | $467.28 |
| 2026-06-07 | 260.99% | 49.05% | -$2.38 | $486.98 |
| 2026-06-04 | 260.99% | 49.05% | -$2.38 | $492.83 |
| 2026-06-03 | 260.99% | 49.05% | -$2.38 | $488.15 |
| 2026-06-02 | 260.99% | 49.05% | -$2.38 | $452.86 |
| 2026-06-01 | 260.99% | 49.05% | -$2.38 | $481.23 |
| 2026-05-31 | 260.99% | 49.05% | -$2.38 | $497.27 |
| 2026-05-28 | 260.99% | 49.05% | -$2.38 | $515.96 |
| 2026-05-27 | 260.99% | 49.05% | -$2.38 | $527.67 |
| 2026-05-26 | 260.99% | 49.05% | -$2.38 | $524.28 |
| 2026-05-25 | 260.99% | 49.05% | -$2.38 | $517.26 |
| 2026-05-24 | 260.99% | 49.05% | -$2.38 | $517.26 |
| 2026-05-21 | 260.99% | 49.05% | -$2.38 | $513.59 |
| 2026-05-20 | 260.99% | 49.05% | -$2.38 | $513.47 |
| 2026-05-19 | 260.99% | 49.05% | -$2.38 | $511.82 |
| 2026-05-18 | 260.99% | 49.05% | -$2.38 | $522.23 |
| 2026-05-17 | 260.99% | 49.05% | -$2.38 | $523.69 |
| 2026-05-14 | 260.99% | 49.05% | -$2.38 | $539.89 |
| 2026-05-13 | 260.99% | 49.05% | -$2.38 | $517.28 |
| 2026-05-12 | 259.98% | 49.05% | -$2.38 | $510.26 |
| 2026-05-11 | 259.98% | 49.05% | -$2.38 | $497.03 |
| 2026-05-10 | 259.98% | 49.05% | -$2.38 | $510.04 |
| 2026-05-07 | 267.91% | 51.59% | -$2.25 | $534.86 |
| 2026-05-06 | 370.55% | 63.89% | -$1.35 | $539.73 |
| 2026-05-05 | 374.80% | 63.82% | -$4.23 | $502.47 |
| 2026-05-04 | 374.80% | 63.82% | -$4.23 | $518.66 |
| 2026-05-03 | 374.80% | 63.82% | -$4.23 | $513.72 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Madrigal Pharmaceuticals Inc (MDGL) has a next-year EPS growth estimate of 259.35%, based on analyst consensus.
When was the latest EPS estimate revision for MDGL?▾
The most recent revision occurred on 2026-06-11, when analysts adjusted the next-year EPS growth estimate from 260.99% to 259.35%.
What sector and industry does Madrigal Pharmaceuticals Inc belong to?▾
Madrigal Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MDGL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Madrigal Pharmaceuticals Inc (MDGL) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports